Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
MSD Files for Keytruda Label Expansion in Ovarian Cancer
MSD said on October 30 that it has filed for approval to add a new indication for its anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of recurrent ovarian cancer.The filing seeks approval for use of Keytruda in combination with chemotherapy…
To read the full story
Related Article
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- Maruho Expands Rapifort Deal with Orient EuroPharma to ASEAN
October 5, 2026
- CellFiber Opens US Base to Drive Adoption of Cell Culture Technology
October 5, 2026
- JCR Licenses Izcargo Rights to Italfarmaco in US, Europe, Latin America
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…